359 related articles for article (PubMed ID: 27581270)
1. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.
Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
Med J Aust; 2016 Sep; 205(5):228-31. PubMed ID: 27581270
[TBL] [Abstract][Full Text] [Related]
2. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy.
Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
Med J Aust; 2016 Aug; 205(4):173-8. PubMed ID: 27510348
[TBL] [Abstract][Full Text] [Related]
3. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
4. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
Ebert T; Jockenhövel F; Morales A; Shabsigh R
Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
[TBL] [Abstract][Full Text] [Related]
6. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
7. Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden EL; Morgentaler A
N Engl J Med; 2004 Jan; 350(5):482-92. PubMed ID: 14749457
[No Abstract] [Full Text] [Related]
8. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
Borst SE; Yarrow JF
Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
[TBL] [Abstract][Full Text] [Related]
9. Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy.
Siddique H; Smith JC; Corrall RJ
Clin Endocrinol (Oxf); 2004 Jan; 60(1):143-5. PubMed ID: 14678301
[No Abstract] [Full Text] [Related]
10. Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk?
Afiadata A; Ellsworth P
Hosp Pract (1995); 2014 Dec; 42(5):69-82. PubMed ID: 25485919
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
Gould DC; Feneley MR; Kirby RS
BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
[TBL] [Abstract][Full Text] [Related]
13. [Testosterone and the prostate].
Sperling H; Rossi R; Lümmen G; Rübben H
Urologe A; 2004 Sep; 43(9):1092-6. PubMed ID: 15368045
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Khera M; Adaikan G; Buvat J; Carrier S; El-Meliegy A; Hatzimouratidis K; McCullough A; Morgentaler A; Torres LO; Salonia A
J Sex Med; 2016 Dec; 13(12):1787-1804. PubMed ID: 27914560
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J
Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313
[TBL] [Abstract][Full Text] [Related]
17. New modalities of transdermal testosterone replacement.
Basaria S; Dobs AS
Treat Endocrinol; 2003; 2(1):1-9. PubMed ID: 15871550
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
19. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
20. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
